How do we improve the long-term consequences of cardiotoxicity in survivors of childhood cancer?

Rudolf K. Steiner, Vivian I. Franco, Steven E Lipshultz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Improvements in long-term childhood cancer survival are attributed to therapies with known cardiotoxic effects. Cardiovascular-related disease is the leading non-cancer-related cause of morbidity and mortality in these survivors. Many of these long-term survivors will develop traditional, modifiable risk factors related to aging, hereditary predisposition, or unhealthy lifestyle behaviors, which further increase their risk of having a cardiac event later in life. Evidence from several long-term, prospective, clinical trials have shown the persistent and progressive nature of anthracycline-induced cardiotoxicity in childhood cancer survivors. However, efforts to find effective primary prevention strategies in children are still ongoing, such as the promising use of the cardioprotectant dexrazoxane. Here we introduce the works presented in the second session of the International Colloquium on Cardio-oncology (Rome, March 12-14, 2014) entitled 'Cardiotoxicity in children, adolescents, and young adults'. Here, presenters addressed the advances and challenges in identifying, preventing, and treating the cardiac late-effects in childhood cancer survivors, and highlighted the long-term cardiovascular complications faced by adult survivors of childhood cancer. Validated cardiac monitoring and screening are now needed to identify early signs of cardiac dysfunction in high-risk childhood cancer patients who would benefit most from tailored,combined preventive measures. Ultimately, the goal is to prevent anthracycline-induced cardiotoxicity altogether without reducing oncologic efficacy.

Original languageEnglish (US)
Pages (from-to)27-30
Number of pages4
JournalProgress in Pediatric Cardiology
Volume36
Issue number1-2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Survivors
Anthracyclines
Neoplasms
Dexrazoxane
Primary Prevention
Life Style
Young Adult
Cardiovascular Diseases
Cardiotoxicity
Clinical Trials
Morbidity
Survival
Mortality
Therapeutics

Keywords

  • Anthracyclines
  • Cardioprotection
  • Dexrazoxane
  • Late cardiotoxicity
  • Long-term survivors
  • Pediatric cardio-oncology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

How do we improve the long-term consequences of cardiotoxicity in survivors of childhood cancer? / Steiner, Rudolf K.; Franco, Vivian I.; Lipshultz, Steven E.

In: Progress in Pediatric Cardiology, Vol. 36, No. 1-2, 2014, p. 27-30.

Research output: Contribution to journalArticle

Steiner, Rudolf K. ; Franco, Vivian I. ; Lipshultz, Steven E. / How do we improve the long-term consequences of cardiotoxicity in survivors of childhood cancer?. In: Progress in Pediatric Cardiology. 2014 ; Vol. 36, No. 1-2. pp. 27-30.
@article{65bbe501e2d64947bcb16f82a0e6aadd,
title = "How do we improve the long-term consequences of cardiotoxicity in survivors of childhood cancer?",
abstract = "Improvements in long-term childhood cancer survival are attributed to therapies with known cardiotoxic effects. Cardiovascular-related disease is the leading non-cancer-related cause of morbidity and mortality in these survivors. Many of these long-term survivors will develop traditional, modifiable risk factors related to aging, hereditary predisposition, or unhealthy lifestyle behaviors, which further increase their risk of having a cardiac event later in life. Evidence from several long-term, prospective, clinical trials have shown the persistent and progressive nature of anthracycline-induced cardiotoxicity in childhood cancer survivors. However, efforts to find effective primary prevention strategies in children are still ongoing, such as the promising use of the cardioprotectant dexrazoxane. Here we introduce the works presented in the second session of the International Colloquium on Cardio-oncology (Rome, March 12-14, 2014) entitled 'Cardiotoxicity in children, adolescents, and young adults'. Here, presenters addressed the advances and challenges in identifying, preventing, and treating the cardiac late-effects in childhood cancer survivors, and highlighted the long-term cardiovascular complications faced by adult survivors of childhood cancer. Validated cardiac monitoring and screening are now needed to identify early signs of cardiac dysfunction in high-risk childhood cancer patients who would benefit most from tailored,combined preventive measures. Ultimately, the goal is to prevent anthracycline-induced cardiotoxicity altogether without reducing oncologic efficacy.",
keywords = "Anthracyclines, Cardioprotection, Dexrazoxane, Late cardiotoxicity, Long-term survivors, Pediatric cardio-oncology",
author = "Steiner, {Rudolf K.} and Franco, {Vivian I.} and Lipshultz, {Steven E}",
year = "2014",
doi = "10.1016/j.ppedcard.2014.09.004",
language = "English (US)",
volume = "36",
pages = "27--30",
journal = "Progress in Pediatric Cardiology",
issn = "1058-9813",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - How do we improve the long-term consequences of cardiotoxicity in survivors of childhood cancer?

AU - Steiner, Rudolf K.

AU - Franco, Vivian I.

AU - Lipshultz, Steven E

PY - 2014

Y1 - 2014

N2 - Improvements in long-term childhood cancer survival are attributed to therapies with known cardiotoxic effects. Cardiovascular-related disease is the leading non-cancer-related cause of morbidity and mortality in these survivors. Many of these long-term survivors will develop traditional, modifiable risk factors related to aging, hereditary predisposition, or unhealthy lifestyle behaviors, which further increase their risk of having a cardiac event later in life. Evidence from several long-term, prospective, clinical trials have shown the persistent and progressive nature of anthracycline-induced cardiotoxicity in childhood cancer survivors. However, efforts to find effective primary prevention strategies in children are still ongoing, such as the promising use of the cardioprotectant dexrazoxane. Here we introduce the works presented in the second session of the International Colloquium on Cardio-oncology (Rome, March 12-14, 2014) entitled 'Cardiotoxicity in children, adolescents, and young adults'. Here, presenters addressed the advances and challenges in identifying, preventing, and treating the cardiac late-effects in childhood cancer survivors, and highlighted the long-term cardiovascular complications faced by adult survivors of childhood cancer. Validated cardiac monitoring and screening are now needed to identify early signs of cardiac dysfunction in high-risk childhood cancer patients who would benefit most from tailored,combined preventive measures. Ultimately, the goal is to prevent anthracycline-induced cardiotoxicity altogether without reducing oncologic efficacy.

AB - Improvements in long-term childhood cancer survival are attributed to therapies with known cardiotoxic effects. Cardiovascular-related disease is the leading non-cancer-related cause of morbidity and mortality in these survivors. Many of these long-term survivors will develop traditional, modifiable risk factors related to aging, hereditary predisposition, or unhealthy lifestyle behaviors, which further increase their risk of having a cardiac event later in life. Evidence from several long-term, prospective, clinical trials have shown the persistent and progressive nature of anthracycline-induced cardiotoxicity in childhood cancer survivors. However, efforts to find effective primary prevention strategies in children are still ongoing, such as the promising use of the cardioprotectant dexrazoxane. Here we introduce the works presented in the second session of the International Colloquium on Cardio-oncology (Rome, March 12-14, 2014) entitled 'Cardiotoxicity in children, adolescents, and young adults'. Here, presenters addressed the advances and challenges in identifying, preventing, and treating the cardiac late-effects in childhood cancer survivors, and highlighted the long-term cardiovascular complications faced by adult survivors of childhood cancer. Validated cardiac monitoring and screening are now needed to identify early signs of cardiac dysfunction in high-risk childhood cancer patients who would benefit most from tailored,combined preventive measures. Ultimately, the goal is to prevent anthracycline-induced cardiotoxicity altogether without reducing oncologic efficacy.

KW - Anthracyclines

KW - Cardioprotection

KW - Dexrazoxane

KW - Late cardiotoxicity

KW - Long-term survivors

KW - Pediatric cardio-oncology

UR - http://www.scopus.com/inward/record.url?scp=84925965951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925965951&partnerID=8YFLogxK

U2 - 10.1016/j.ppedcard.2014.09.004

DO - 10.1016/j.ppedcard.2014.09.004

M3 - Article

AN - SCOPUS:84925965951

VL - 36

SP - 27

EP - 30

JO - Progress in Pediatric Cardiology

JF - Progress in Pediatric Cardiology

SN - 1058-9813

IS - 1-2

ER -